Helen M. Dodds

Queen's Medical Centre — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

16h-index624citations33works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer therapeutics and mechanisms(14), Cancer Treatment and Pharmacology(7), Lung Cancer Research Studies(6), Cholinesterase and Neurodegenerative Diseases(3), Pregnancy and preeclampsia studies(2)

Publications33 total

Meeting the needs of young people in hospital
Paediatric Care·2010· 5 cited
Meeting the needs of young people in hospital
Paediatric Care·2010· 2 cited
The relative contributions of carboxylesterase and β-glucuronidase in the formation of SN-38 in human colorectal tumours
Oncology Reports·2003· 17 cited
High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma
Journal of Chromatography B·2003· 42 cited
The inhibition of acetylcholinesterase by irinotecan and related camptothecins: key structural properties and experimental variables.
PubMed·2002· 16 cited
The Importance of Tumor Glucuronidase in the Activation of Irinotecan in a Mouse Xenograft Model
Journal of Pharmacology and Experimental Therapeutics·2002· 14 cited
Comment on a Published Paper
British Journal of Pharmacology·2001Open Access
Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction
Anti-Cancer Drugs·2001· 19 cited
Novel aspects of the metabolism & toxicology of the chemotherapeutic agent, Irinotecan (CPT-11)
2001
Pharmacokinetics of [35s] PI-88 in rats
Queensland's institutional digital repository (The University of Queensland)·2001
Pharmacokinetics of [ 35 S]PI-88 in male rats
2001
Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance
Cancer Chemotherapy and Pharmacology·2000· 17 cited
The Mechanism for the Inhibition of Acetylcholinesterases by Irinotecan (CPT-11)
Molecular Pharmacology·1999· 64 cited
The Mechanism for the Inhibition of Acetylcholinesterases by Irinotecan (CPT-11)
Molecular Pharmacology·1999· 3 cited
More About: Irinotecan-Related Cholinergic Syndrome Induced by Coadministration of Oxaliplatin
JNCI Journal of the National Cancer Institute·1999· 21 citedOpen Access
Plasma Indomethacin Assay Using High-Performance Liquid Chromatography-Electrospray-Tandem Mass Spectrometry: Application to Therapeutic Drug Monitoring and Pharmacokinetic Studies
Therapeutic Drug Monitoring·1998· 17 cited
The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry
Journal of Pharmaceutical and Biomedical Analysis·1998· 24 cited
Identification of a New Metabolite of CPT-11 (Irinotecan): Pharmacological Properties and Activation to SN-38
Journal of Pharmacology and Experimental Therapeutics·1998· 113 cited
Photodegradation of Irinotecan (CPT-11) in Aqueous Solutions: Identification of Fluorescent Products and Influence of Solution Composition
Journal of Pharmaceutical Sciences·1997· 36 cited
A Reference Method for the Analysis of Aldosterone in Blood by High-Performance Liquid Chromatography–Atmospheric Pressure Chemical Ionization–Tandem Mass Spectrometry
Analytical Biochemistry·1997· 61 cited
page 1 of 2Next →

Frequent Co-authors

Laurent P. Rivory(13), Paul J. Taylor(5), G. R. Cannell(4), Susan M. Pond(4), George Clark(4), Jacques Robert(3), Anthony G. Johnson(3), R.H. Mortimer(3), James F. Bishop(3), Stephen Clarke(3), Suzan K. Hanna(2), Les Johnson(2), Peter Tobin(2), Brian R. Creese(2), Vito Ferro(2), Andrew R. King(2), Karine Mardon(2), R. G. Dickinson(2), Malcolm Punler(2), Marie‐Christine Haaz(1)